Results from the large-scale NRG-GU005 clinical trial show that stereotactic body radiation therapy for intermediate-risk prostate cancer significantly improves bowel quality of life and reduces severe genitourinary toxicity compared to moderately hypofractionated IMRT, though disease-free survival favored moderately hypofractionated IMRT after median follow-up.
When men diagnosed with intermediate-risk prostate cancer weigh their treatment options, the debate often centers on balancing cancer control against long-term side effects and time demands. A major clinical trial presented at the American Society for Radiation Oncology Annual Meeting and published in the Journal of the American Medical Association provides new clarity on how two advanced radiation schedules stack up against one another.
The Phase III NRG-GU005 trial enrolled 698 evaluable patients across 136 international centers to compare stereotactic body radiation therapy, commonly known as SBRT, with moderately hypofractionated intensity-modulated radiation therapy, or MH-IMRT. Participants in the SBRT arm received a total dose of 36.25 Gy delivered in 5 fractions, while those in the IMRT arm received either 70 Gy in 28 fractions or 60 Gy in 20 fractions.
Bowel Health Quality of Life and Toxicity Findings
The study met key quality-of-life objectives by demonstrating that SBRT improved bowel health related quality of life compared to the longer IMRT regimens. Specifically, fewer patients in the SBRT group experienced a minimally clinically important difference in bowel domains at two years—34.9% versus 43.8% for IMRT.
Furthermore, patients receiving SBRT experienced significantly fewer grade 3 or 4 genitourinary adverse events, recording a rate of 0.6% compared to 2.5% in the IMRT group. Longitudinal analysis also revealed that SBRT patients reported better outcomes concerning urinary incontinence and the maintenance of erectile function, alongside a lower incidence of bowel issues.
Disease-Free Survival and Futility Boundaries
Despite the favorable quality-of-life metrics, the trial did not achieve superiority in its cancer control endpoints. The disease-free survival co-primary endpoint was reported early because an interim analysis crossed the futility boundary, indicating that SBRT was not superior to hypofractionated IMRT for disease control in this population.
The 3-year disease-free survival rate favored moderately hypofractionated IMRT at 92.1% compared with 88.6% for SBRT. Investigators noted that biochemical failure, determined by prostate-specific antigen measurements, was higher in the SBRT arm, pointing to a narrow separation between tumor control and normal tissue preservation.
“This major clinical trial teaches us not only about state-of-the-art radiation technology, but also about the biology of radiation effects on prostate cancer and normal organs responsible for basic human functions.”
Dr. Mitchell Machtay, Penn State and NRG Group Deputy Chair and Chief Scientific Officer
Context Within Prior Radiotherapy Trials
The findings from NRG-GU005 arrive alongside other major evaluations in the field, including the PACE-B trial, which previously showed that SBRT was non-inferior to conventional or moderately hypofractionated radiation regarding clinical and biochemical failure rates.
Editorial commentators publishing alongside the primary study emphasized that radiation dose remains a principal driver of biochemical control. They suggested that future investigations should evaluate methods to safely escalate dose in an SBRT framework while maintaining low toxicity profiles.
“Ultimately, the most important message … may be that optimizing prostate cancer outcomes requires attention to a constellation of treatment parameters rather than a singular focus on fractionation schedule.”
Stanley L. Liauw, MD, University of Chicago, and W. Robert Lee, MD, Duke University Medical Center
Clinical Implications for Patients and Physicians
While SBRT offers undeniable logistical advantages—requiring only five outpatient visits compared to twenty or more for standard fractionation—clinicians must weigh convenience against the observed numerical differences in medium-term disease control. The trial highlights that reducing treatment time does not automatically translate to equivalent biological dosing intensity.
As radiation oncology continues to adapt, researchers stress that longer follow-up of the NRG-GU005 cohort will be essential to determine whether the early divergence in biochemical control persists or widens over time. For now, physicians and patients discussing localized intermediate-risk prostate cancer have concrete data to balance fewer short-term side effects against the nuances of long-term biochemical survival.
